Community pharmacists need more support and resources to provide quality contraceptive counseling and care, according to a study published in BMJ Sexual and Reproductive Health.
Danielle Mazza, MD, MBBS, FRACGP, DRANZCOG, department head of the Monash University Department of General Practice in Notting Hill, Victoria, Australia, and colleagues conducted the study. The research focused on Australian community pharmacies to find how contraceptive care is practiced and how it might be improved.
“We examined community pharmacists’ contraceptive knowledge and their attitudes, practices and perceived barriers to and benefits of contraceptive counselling provision,” Mazza and colleagues said.
Researchers noted how community pharmacies in Europe and North America have increased access to sexual and reproductive health due to task-sharing.
“These community pharmacy task-sharing initiatives include pregnancy options counselling, interventions integrating contraceptive care across community and clinic-based services, and legislative amendments providing pharmacists with practice licensing authority to dispense hormonal contraception without a physician's prescription,” the authors wrote.1-4
Between September and December 2020, study authors conducted a nationwide survey by mail. They contacted 2149 community pharmacies and requested a response from a single pharmacist from each location. Nineteen percent (366) of requests were answered, with a median respondent age of 34 years old.
Outcomes from the survey included practices, reported and tested knowledge, attitudes, confidence, benefits, and barriers.1
Most pharmacists (85%), “agreed that contraceptive counselling fits within their current professional activities and emphasized benefits to their patients, including improved access to contraceptive decision support (80%), as being key motivators of counselling,” Mazza and colleagues reported.
Researchers said the most important barriers included lack of assistance tools (54%), lack of training opportunities (5%), and lack of payment mechanisms (66%).
Pharmacists rated their self-knowledge and confidence as highest with combined oral contraceptives and lowest with copper intrauterine devices.
“When tested, pharmacists were very knowledgeable about method, dosage, frequencies and costs, and relatively less knowledgeable about side-effects and IUD suitability for adolescents,” Mazza and colleagues said.
They added that Australian pharmacists have limited opportunities after undergraduate degrees for contraceptive knowledge, which is similar to findings in the United States, where “most pharmacists described contraceptive education in the pharmacy curricula as being inadequate to prepare them for contraception prescribing.”1,5
In areas where general practitioners were scarce, pharmacies were most likely to have a private consultation room and advanced accreditation, according to study authors. They said this provides an opportunity for pharmacists to increase access to contraception methods and counselling in communities that lack these services, and that most pharmacists felt positive about these services.1
To decrease barriers reported by pharmacists, researchers recommended policy level changes such as medicine rebates and federal pharmacy funding agreements. In addition, they said pharmacy curricula changes and professional development opportunities would also decrease these barriers.
For study limitations, researchers said that 2/3 of pharmacists who responded to the survey self-identified as innovators or early adopters, and so this may have resulted in sampling bias.
In addition, while the sample size of 366 responses was adequate, it was a relatively small number compared with the initial 2149 survey requests and may not provide a full picture.
Researchers said that Australian community pharmacists know contraceptive counseling is good for both public health and for patients. They said pharmacists reported being enthusiastic about expanding their scope of practice for contraceptive care.1
“Community pharmacists provide contraceptive information and counselling but lack the necessary resources and support to be able to consistently provide quality, person-centered care,” researchers concluded.
They said that payment mechanisms, pharmacy-specific professional resources, and training opportunities need additional exploration to provide support for pharmacists to offer high quality, patient-centered contraceptive care.1
References
Daré Bioscience initiates phase 3 clinical trial for ovaprene contraceptive
December 5th 2023Daré Bioscience has commenced a pivotal phase 3 clinical trial for ovaprene, an intravaginal contraceptive that releases a locally acting agent to prevent sperm entry into the cervical canal, marking a significant step towards a non-hormonal contraceptive option for women.
Read More
Recap on reproductive rights with David Hackney, MD, MS
December 20th 2022In this episode of Pap Talk, we spoke with David Hackney, MD, MS, maternal-fetal medicine physician at Case Western Reserve University and chair of ACOG's Ohio chapter for a full recap of where restrictions on reproductive rights have been and where they're going.
Listen
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Listen
Treating heavy menstrual bleeding: Levonorgestrel system vs combined oral contraceptives
November 8th 2023In a recent study, patients who were treated for heavy menstrual bleeding with the levonorgestrel intrauterine system had similar changes in bleeding-related quality of life as those using combined oral contraceptives for treatment.
Read More
Enhancing contraceptive use among female smokers
October 26th 2023Women of reproductive age often use combined hormonal contraceptives, which are available orally, as a vaginal ring, or as a transdermal patch. However, CHCs are associated with increased risks of venous thromboembolism and myocardial infarction (MI).
Read More